Monopar Therapeutics Inc (MNPR) has received a new Buy rating, initiated by JonesTrading analyst, Soumit Roy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors surrounding Monopar Therapeutics Inc. The company has made significant strides with its acquisition of ALXN1840, a drug initially discontinued by AstraZeneca despite successful Phase 3 trials. Monopar aims to address the methodological issues in calculating copper balance in Wilson’s Disease patients, which could potentially lead to the drug becoming the first approved treatment for this condition.
Moreover, the market for Wilson’s Disease in the US and EU5 is substantial, estimated to be over $2.5 billion. With Monopar’s drug showing promise in addressing copper mobilization, there is a projected market penetration and peak sales potential of approximately $500 million. While regulatory risks remain, the path towards FDA approval seems viable, with expectations for a successful filing by the first half of 2026. These factors contribute to the optimistic outlook and the Buy rating with a price target of $130.
In another report released on October 8, Cantor Fitzgerald also maintained a Buy rating on the stock with a $109.00 price target.